SLC5A2 and diabetes mellitus: In real-world clinical practice, patients with MAFLD and DM who were newly prescribed SGLT2 inhibitors showed significantly better improvement in liver enzymes, reduction in BMI and waist circumference, and a decrease in FLI than those who were newly prescribed DPP4 inhibitors.